Advances in the computational landscape for repurposed drugs against COVID-19

被引:18
作者
Aronskyy, Illya [1 ]
Masoudi-Sobhanzadeh, Yosef [2 ]
Cappuccio, Antonio [1 ]
Zaslavsky, Elena [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA
[2] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Biomed Inst, Tabriz, Iran
基金
美国国家卫生研究院;
关键词
Computational drug repurposing; COVID-19; SARS-CoV-2; Docking and molecular dynamics; Structure-guided machine learning; Virus-host interaction network analysis; CORONAVIRUS; DOCKING; COMPLEMENT; SARS-COV-2; KNOWLEDGE; HELICASE; DATABASE; BINDING; DESIGN;
D O I
10.1016/j.drudis.2021.07.026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The COVID-19 pandemic has caused millions of deaths and massive societal distress worldwide. Therapeutic solutions are urgently needed, but de novo drug development remains a lengthy process. One promising alternative is computational drug repurposing, which enables the prioritization of existing compounds through fast in silico analyses. Recent efforts based on molecular docking, machine learning, and network analysis have produced actionable predictions. Some predicted drugs, targeting viral proteins and pathological host pathways are undergoing clinical trials. Here, we review this work, highlight drugs with high predicted efficacy and classify their mechanisms of action. We discuss the strengths and limitations of the published methodologies and outline possible future directions. Finally, we curate a list of COVID-19 data portals and other repositories that could be used to accelerate future research.
引用
收藏
页码:2800 / 2815
页数:16
相关论文
共 50 条
  • [1] Perspective: repurposed drugs for COVID-19
    Na-Bangchang, Kesara
    Porasuphatana, Supatra
    Karbwang, Juntra
    ARCHIVES OF MEDICAL SCIENCE, 2022, 18 (05) : 1378 - 1391
  • [2] Impact of repurposed drugs on the symptomatic COVID-19 patients
    Hussain, Iqbal
    Hussain, Afzal
    Alajmi, Mohamed F.
    Rehman, Md Tabish
    Amir, Samira
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2021, 14 (01) : 24 - 38
  • [3] Repurposed GI Drugs in the Treatment of COVID-19
    Aguila, Enrik John T.
    Cua, Ian Homer Y.
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (08) : 2452 - 2453
  • [4] Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics
    Chatterjee, Bhaswati
    Thakur, Suman S.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19
    Das, Gourab
    Das, Troyee
    Chowdhury, Nilkanta
    Chatterjee, Durbadal
    Bagchi, Angshuman
    Ghosh, Zhumur
    GENOMICS, 2021, 113 (01) : 1129 - 1140
  • [6] Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19
    Bibi, Nousheen
    Gul, Sana
    Ali, Johar
    Kamal, Mohammad Amjad
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 885
  • [7] Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
    Punekar, Madhura
    Kshirsagar, Manas
    Tellapragada, Chaitanya
    Patil, Kanchankumar
    MICROBIAL PATHOGENESIS, 2022, 168
  • [8] An Overview of Repurposed Drugs for Potential COVID-19 Treatment
    Govender, Kamini
    Chuturgoon, Anil
    ANTIBIOTICS-BASEL, 2022, 11 (12):
  • [9] Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment
    Martinez, Miguel Angel
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [10] Brief review on repurposed drugs and vaccines for possible treatment of COVID-19
    De, Priyasha
    Chakraborty, Ishita
    Karna, Bhargavi
    Mazumder, Nirmal
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 898